Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 2Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Conditions

Tuberous Sclerosis 3Seizures 3Tuberous Sclerosis 2 1Tuberous Sclerosis 1 1Spasms, Infantile 1Lennox Gastaut Syndrome 1Epilepsy 1Epilepsies, Myoclonic 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Cannabidiol × Clear all
NCT04485104 2025-10-31

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

Jazz Pharmaceuticals

Phase 3 Terminated
3 enrolled 28 charts

Tuberous Sclerosis 1, Tuberous Sclerosis 2, Epilepsy, Epilepsies, Myoclonic, Seizures, Spasms, Infantile, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT02544763 2022-09-28

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Jazz Pharmaceuticals

Phase 3 Completed
224 enrolled 18 charts

Seizures, Tuberous Sclerosis

NCT02544750 2022-07-14

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Jazz Pharmaceuticals

Phase 3 Completed
199 enrolled 14 charts

Seizures, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡